Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Phathom Pharmaceuticals Inc
(NQ:
PHAT
)
12.81
-0.17 (-1.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Recap: Phathom Pharmaceuticals Q3 Earnings
November 09, 2023
Via
Benzinga
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 01, 2023
Via
Benzinga
Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity
May 24, 2023
Via
Benzinga
Analyst Expectations for Phathom Pharmaceuticals's Future
May 11, 2023
Via
Benzinga
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
What's Going On With Phathom Pharmaceuticals Stock?
October 30, 2023
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo
Via
Benzinga
Exposures
Product Safety
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
October 25, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
October 13, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc.
Via
Benzinga
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 21, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 10, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
August 09, 2023
Via
Benzinga
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
August 07, 2023
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors.
Via
InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 12, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
June 04, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
June 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
May 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
May 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 23, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 23, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 23, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
May 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
May 11, 2023
Via
Benzinga
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 10, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.